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Summary
Expression of the Kaposi’s sarcoma-associated herpesvirus (KSHV) cyclin D homolog, K cyclin, is thought to contribute
to viral oncogenesis. We show that K cyclin expression in primary cells sensitizes to apoptosis and induces growth arrest,
both of which are dependent on p53 but independent of E2F1 or p19ARF. DNA synthesis, but not cytokinesis, continues in
K cyclin-expressing cells, leading to multinucleation and polyploidy. Such polyploid cells exhibit pronounced centrosome
amplification and consequent aneuploidy. Our data suggest that K cyclin expression leads to cytokinesis defects and
polyploidy, which activates p53. However, in the absence of p53, such cells survive and expand as an aneuploid population.
Corroborating these findings, in vivo E K cyclin expression cooperates with p53 loss in the induction of lymphomas.
Introduction Jung et al., 1994; Li et al., 1997). Such K cyclin/Cdk complexes
are refractory to inhibition by CDK inhibitors (Jeffrey et al., 2000;
Swanton et al., 1997). Another unique feature of K cyclin/Cdk6Infection of human B lymphocytes and endothelial cells with
Kaposi’s sarcoma-associated herpesvirus (KSHV, a.k.a. HHV-8) complexes is that they potently phosphorylate an extended
array of substrates that are not normally targets of cellular cyclinpredisposes carriers to the development of certain B cell malig-
nancies (primary effusion lymphoma [PEL] and Multicentric Cas- D/Cdk6. These include the cyclin E/Cdk2 targets p27Kip1, Id-2,
and Cdc25A (Ellis et al., 1999; Mann et al., 1999) and the cyclintleman’s disease [MCD]) and the skin tumor Kaposi’s sarcoma
(KS) (Chang et al., 1994). The majority of tumor cells in such A/Cdk2 targets of the replication machinery Cdc6 and Orc1
(Laman et al., 2001). K cyclin phosphorylation of p27Kip1 triggersneoplasms are latently infected (Boshoff et al., 1995; Zhong et
al., 1996), suggesting that latent genes are important for viral its degradation, further facilitating the activation of endogenous
cyclin/Cdk complexes. Thus, the activity of the K cyclin/Cdk6pathogenesis. One latently expressed candidate KSHV onco-
gene encodes K cyclin, which is structurally related to cellular complex in part mimics the combined activities of G1 and S
phase cyclin/Cdk complexes. This is consistent with the abilityG1 D-type cyclins.
D-type cyclins form active holoenzymes with Cdk4 or Cdk6, of K cyclin, unlike cyclin D, to initiate DNA replication in an in
vitro replication system (Laman et al., 2001) and to enforce Sand their major role appears to be to initiate inhibitory phosphor-
ylation of the Retinoblastoma (Rb) protein. Subsequent Rb phase entry in quiescent cells or in cells arrested by CDK inhibi-
tors (Swanton et al., 1997). Such properties of K cyclin supportphosphorylation via cyclin E/Cdk2 complexes inactivates Rb
and thereby liberates the E2F transcription factors, driving entry the notion that it can function as an oncogenic protein, although
no such role for K cyclin has yet been reported.into S phase (Lundberg and Weinberg, 1998). However, cyclin
E/Cdk2 complexes also have Rb-independent functions, since In addition to driving cell cycle progression, K cyclin/Cdk6
complexes can, like many other oncogenic proteins, triggercyclin E is required for the G1/S transition in Rb-deficient cells
(Ohtsubo et al., 1995). Indeed, Cdk2, in complex with either apoptosis (Ojala et al., 1999), although the molecular mecha-
nisms underlying K cyclin-induced apoptosis are largely un-cyclin E or cyclin A, can phosphorylate proteins of the replication
machinery like Cdc6, directly activating DNA replication (Jiang known. Endogenous cell growth-deregulating oncoproteins,
such as c-Myc or E2F-1, induce apoptosis via discrete pathwayset al., 1999).
In vitro studies have shown that KSHV K cyclin can interact that can sensitize the cell to a wide variety of proapoptotic
insults, including ligation of TNF/TRAIL/FAS family death recep-with all Cdks, although it favors Cdk6 (Godden-Kent et al., 1997;
S I G N I F I C A N C E
Infection of human B lymphocytes or endothelial cells by Kaposi’s sarcoma-associated herpesvirus (KSHV) predisposes carriers to
the development of lymphoproliferative disorders and the skin cancer Kaposi’s sarcoma. Most such malignant cells are latently
infected with KSHV, and K cyclin is one of the few latently expressed genes. K cyclin/Cdk complexes exhibit several unique features
that promote proliferation, including resistance to Cdk inhibitors. Our study shows that the tumorigenicity of K cyclin is greatly
enhanced in the absence of the p53 tumor suppressor pathway. Furthermore, our finding that the mitogenic effects of K cyclin are
antagonized by p53 provides an explanation for the presence of a set of p53-inhibiting proteins in the KSHV genome and suggests
that pharmacological disruption of this inhibition may be a potential means of anti-KSHV therapy.
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tors and survival factor deprivation (Evan et al., 1992; Hueber
et al., 1997; Klefstrom et al., 1997; Phillips et al., 1999). Onco-
genic c-Myc is thought to mediate its proapoptotic effect by
promoting the release of holo-cytochrome c (cyt c) from the
mitochondria into the cytosol (Juin et al., 1999). Interestingly,
K cyclin/cdk6 complexes can phosphorylate and inactivate cel-
lular Bcl-2 (Ojala et al., 2000), a key regulator of cytochrome c
release from mitochondria, suggesting that K cyclin expression,
at least under certain circumstances, may directly interfere with
mitochondrial integrity.
Another well-characterized proapoptotic pathway activated
by oncoproteins like E2F1, E1A, c-Myc, and Ras is the ARF/
p53 pathway (Bates et al., 1998; de Stanchina et al., 1998;
Palmero et al., 1998; Zindy et al., 1998). Activation of such
oncoproteins can induce upregulation of p19ARF (or human
p14ARF) protein, which then associates directly with Mdm2 pro-
tein and neutralizes its ability to promote the ubiquitination and
degradation of p53 (Kamijo et al., 1998; Pomerantz et al., 1998;
Zhang et al., 1998). This results in p53 stabilization and conse-
quent cell cycle arrest or apoptosis.
In this study we have explored the consequences of K cyclin
expression in human and mouse primary cells. We show that
expression of K cyclin in primary cells blocks cytokinesis; yet,
it simultaneously drives DNA replication. Our data suggest that
the resulting polyploidy, rather than the E2F1/p19ARF pathway,
activates p53, thereby triggering growth arrest and apoptosis.
Loss of p53 dramatically exacerbates K cyclin-induced lympho-
magenesis in vivo, indicating that growth arrest and/or apopto-
sis induced by K cyclin must be overcome in order for its onco-
genic potential to be revealed.
Results
Expression of K cyclin in MEFs sensitizes cells to
apoptosis induced by DNA damage, death receptor
ligation, and survival factor deprivation
To explore the molecular mechanism of K cyclin-induced apo-
ptosis, we used the pBMNIresEGFP (K cyclin pBMN) retrovirus
vector to express K cyclin in early passage mouse embryo Figure 1. Expression of K cyclin sensitizes MEFs to death triggered by various
fibroblasts (MEFs). This vector dicistronically directs the con- stress signals
Wt MEFs were infected for 2 subsequent days with KpBMN or empty vectorcomitant expression of K cyclin and green fluorescent protein
and were next cultured for 48 hr in medium containing 10% FBS, 0.2% FBS,(GFP). Following transduction, around 80% of the cells were
or 10% FBS supplemented with etoposide (5.0 M), TNF (50 ng/ml), or TRAILGFP positive, and apoptotic cells in this population were identi-
(200 ng/ml). Floating and adhered cells were collected and stained with
fied by Annexin V-PE and Via-Probe staining using flow cytomet- Annexin V-PE and Via-Probe, followed by flow cytometric analysis, an exam-
ric analysis (Figure 1, upper panel). We observed no significant ple of which is shown in the upper panel. The mean percentages of dead
cells  SEM of three independent experiments are shownincrease in apoptosis in K cyclin-expressing cells grown in 10%
FBS (around 8%, compared with 3% upon mock infection) (Fig-
ure 1, lower panel). Next, we examined whether expression
of K cyclin sensitizes cells to other triggers of apoptosis by
DNA damage, death receptor ligation, and survival factor depri-subjecting K cyclin-expressing cells to various proapoptotic
vation.stimuli for 48 hr. Treatment of control MEFs with low (0.2%)
serum, with the DNA damaging agent etoposide, or with TNF
K cyclin-induced apoptosis requires p53,or TRAIL induced no significant cell death (around 5%–12%
but not E2F1 or p19ARFapoptosis) during the course of the experiment: in contrast, all
A common mechanism by which oncoproteins trigger apoptosisof these insults induced pronounced apoptosis in MEFs ex-
is via the p19ARF/p53 pathway. In human cells, E2F1 directlypressing K cyclin (Figure 1, lower panel). The sensitization to
activates expression of p14ARF by activating transcription fromapoptosis by K cyclin was especially evident in cells grown in
the p14ARF promoter (Bates et al., 1998). Since expression of K0.2% FBS, where nearly 40% of the K cyclin-expressing cells
cyclin leads to strong phosphorylation of Rb (Child and Mann,underwent apoptosis. These data demonstrate that K cyclin
expression sensitizes MEFs to the induction of apoptosis by 2001) and subsequent release of E2Fs, we asked whether the
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To examine a potential role for p53 in K cyclin-induced
apoptosis, we first analyzed whether p53 protein levels are in-
creased upon K cyclin expression. Retroviral expression of K
cyclin in MEFs growing in 10% FBS resulted in an upregulation
of p53 protein (Figure 2B). Induction of p53 protein levels corre-
lated with an increase in the levels of the p53 target gene p21Cip1
(Figure 2C), implying an upregulation of transcriptionally active
p53 protein upon K cyclin expression. Strikingly, K cyclin ex-
pression in E2F1/ or ARF/ MEFs also resulted in an
increase in active p53 protein levels (Figures 2B and 2C). Thus,
neither E2F1 nor p19ARF is required for the activation of p53 by
K cyclin.
Next, we determined the requirement of p53 in K cyclin-
induced apoptosis. K cyclin was transduced into wild-type (wt),
E2F1/, ARF/, and p53/ MEFs, followed by growth of
cells for 48 hr in 0.2% FBS. Levels of apoptosis induced by K
cyclin were similar in wt, E2F1/, and ARF/ MEFs. In
contrast, K cyclin induced substantially less apoptosis in
p53/ MEFs as compared to wt MEFs (15% in p53/ cells
compared to about 38% in other MEFs, Figure 2D). These data
show that K cyclin-induced apoptosis does not require p19ARF
or E2F1, although a significant component of apoptosis is p53
dependent.
K cyclin expression triggers a p53-dependent, but
p21Cip1-independent, growth arrest
During the course of these studies, we noticed that K cyclin-
expressing cells exhibited a large and flattened phenotype and
that cultures could not be propogated. Oncogenes such as Ras
can trigger growth arrest in primary cells (Serrano et al., 1997),
and this prompted us to investigate whether K cyclin could also
induce growth arrest in MEFs.
We first determined the cell proliferation capacity of mock
and K cyclin-transduced MEF populations. Mock-infected wt,Figure 2. P19ARF and E2F1 expression are dispensable, but p53 is required for
apoptosis induced by K cyclin E2F1/, and ARF/ cells proliferated until they reached
A: K cyclin does not induce p19ARF expression in MEFs. Wt MEFs were infected confluence (Figure 3A, closed symbols), whereas cells trans-
with K cyclin-encoding (K) or empty virus (V). Infected cells were selected duced with K cyclin (Figure 3A, open symbols) showed no net
by puromycin and were grown for 72 hr in medium containing 10% FBS. propagation. No such inhibition of cell proliferation was ob-p53/ MEFs are shown as a positive control, since they contain high
served upon ectopic expression of cellular cyclin D3 in wt MEFs,levels of endogenous p19ARF due to the lack of a p53-mediated negative
although protein expression was readily detectable by immu-feedback loop (Stott et al., 1998). Lysates were prepared and analyzed by
immunoblotting with anti-p19ARF antibody. B: K cyclin expression is associ- noblotting (data not shown). Importantly, K cyclin-expressing
ated with elevated p53 levels. MEFs of the indicated genotype were in- p53/MEFs expanded until confluent, although the prolifera-
fected with empty (V) or K cyclin-encoding pBabepuro (K) vector. Infected
tion rate was somewhat reduced compared with that in mock-cells were selected by puromycin and were grown for 72 hr in medium
infected cells (Figures 3A and 3B). K cyclin-expressing p53/containing 10% FBS until cell lysates were prepared. As a control, a subcon-
fluent culture of wt MEFs was exposed to 8 GY of -irradiation and was MEFs could be kept in culture for at least 3 weeks (data not
grown for an additional 24 hr. Proteins were immunoblotted with CM-5 p53 shown), showing that p53/ MEFs can tolerate the presence
or -actin antibody. C: Protein lysates from MEFs infected as in B were of K cyclin for an extended period of time.analyzed by immunoblotting with anti-Flag antibody to detect tagged K
The lack of a net propagation of K cyclin-expressing cellscyclin or with CM-5 p53, p21Cip1, or -actin antibody. D: Wt, E2F1/,
might result either from an elevated rate of apoptosis relativeARF/, and p53/ MEFs were infected for 2 subsequent days with
KpBMN or empty vector, followed by growth for 48 hr in 10% FBS- or 0.2% to proliferation, or from an absence of proliferation due to a
FBS-containing medium. Cells were stained with Annexin V-PE and Via- block in cell division. To investigate whether K cyclin blocks cell
Probe and were analyzed by flow cytometry to determine the percentage
division, we performed time-lapse videomicroscopy to followof apoptotic cells in the GFP-positive cell population.
cultures of infected MEFs. Representative QuickTime movies of
these experiments can be viewed in the Supplementary Material
available with this article online (http://www.cancercell.org/cgi/
content/full/2/3/229/DC1). The quantitation of cell divisions inp19ARF protein level is upregulated in MEFs upon K cyclin expres-
these movies show that, while mock-infected wt MEFs prolifer-sion. K cyclin protein was retrovirally expressed in MEFs growing
ate to confluence, K cyclin-expressing wt, E2F1/, andin 10% FBS, and, 72 hr later, the cells were assayed for p19ARF
ARF/ MEFs failed to divide at all (see Figure 3C for wt MEFsprotein expression by immunoblotting. However, we observed
expressing K cyclin). However, p53/ MEFs expressing Kno upregulation of p19ARF protein upon K cyclin expression (Fig-
ure 2A). cyclin divided and proliferated until confluent (Figure 3C). Taken
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Figure 3. K cyclin-expressing MEFs show a p53-
dependent growth arrest
A: Growth curves of MEFs constitutively express-
ing K cyclin. Wt, E2F1/, p53/ , or ARF/
MEFs were transduced with empty or K cyclin-
encoding pBabepuro retrovirus. Transduced
cells were selected by puromycin and were
grown in medium containing 10% FBS. Cells were
plated at 0.5  105 cells per well at day 0, and
cell numbers were counted 1, 3, and 5 days later.
The experiment was repeated three times with
essentially similar results, and the growth curves
represent the average of these experiments. B:
Microscopic analysis of cells at day 5 of the
growth curve. Phase-contrast pictures were
taken at a magnification of 10. C: Cultures of
MEFs transduced and cultured as in A were fol-
lowed by time-lapse videomicroscopy (see the
Supplementary Material for QuickTime movies).
Pictures were taken every 10 min, and cultures
were followed for 4 days. Movies were analyzed
for cell divisions, and cumulative cell divisions of
wt or p53/MEFs expressing K cyclin were plot-
ted. D: Growth curves of p21/ MEFs infected
with empty of K cyclin-encoding pBabepuro ret-
rovirus and analyzed as in A.
together, these data imply that constitutive expression of K exhibited large multilobular nuclei. This suggested to us that,
despite defective cell division in K cyclin-expressing cells, DNAcyclin not only induces apoptosis but also blocks cell division
via a mechanism that does not require E2F1 or p19ARF, but does replication was still taking place.
To determine whether MEFs arrested upon K cyclin expres-require p53.
p53-dependent growth arrest is often attributed to the Cdk- sion maintained DNA synthesis, cells were transduced with K
cyclin and were cultured for 3 days in the presence of serum.inhibitory action of the p21Cip1 protein (Stewart and Pietenpol,
2001). Since p21Cip1 accumulates in cells expressing K cyclin Subsequently, they were labeled for 5 hr with BrdU and were
analyzed by flow cytometry. A significant percentage of cells(Figure 2C), we asked whether K cyclin expression results in
expressing K cyclin had entered S phase over the course ofthe arrest of p21/ MEFs. A lack of p21Cip1 did not mitigate
BrdU labeling (Figure 4B), with percentages being roughly equiv-the K cyclin-induced growth arrest (Figure 3D and Movie S1).
alent to mock-infected cultures. To confirm that the observed
multinuclear cells had incorporated BrdU, we examined theIncrease in multincleation and polyploidy
upon K cyclin expression cells by immunofluorescence microscopy using an anti-BrdU
antibody. BrdU staining was observed in the K cyclin-expressingTime-lapse analysis of K cyclin-expressing cells indicated that
cells and their nuclei enlarged over time. We also frequently growth-arrested MEFs with large or multiple nuclei (Figure 4C,
arrows), indicating that these cells had synthesized DNA.observed that the cell nuclei divided without concomitant cell
division, yielding cells with multiple nuclei (Figure 4A). This phe- MEFs comprise a heterogeneous cell population, and some
multinucleation and polyploidy occurs spontaneously. Wenotype was seen in both wild-type and in p53/ MEFs ex-
pressing K cyclin, but it was more dramatic in the latter, which therefore quantitated polyploidy by DNA staining and flow cyto-
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Figure 4. Growth-arrested K cyclin-expressing
MEFs synthesize DNA
A: K cyclin-expressing cells become multinucle-
ated. Cultures were infected and grown as in
Figure 3A and were microscopically analyzed at
day 5 of the growth curve. DNA was counter-
stained with Hoechst. Pictures were taken at a
magnification of 32. B: Wt, E2F1/, ARF/,
or p53/ MEFs were infected as described in
Figure 3A and were grown for 3 days. BrdU (50
M) was added to the medium, and the cells
were grown for an additional 5 hr. Cells were
collected and stained with PI and anti-BrdU-FITC
conjugate and were analyzed by flow cytome-
try. The percentages of BrdU-positive cells are
indicated. C: Cells infected as in Figure 3A were
grown on coverslips for 3 days, followed by
growth in medium containing BrdU for 5 hr. Cells
were fixed in 70% ethanol and were stained with
anti-BrdU-FITC (green) and Hoechst (blue) for
DNA. Slides were microscopically analyzed, and
pictures were taken at a magnification of 32.
A large, multinucleated BrdU-positive cell is indi-
cated with an arrowhead.
metric analysis. Mock- and K cyclin-transduced MEFs were level of 26%). These data show that a significant proportion of
the MEFs expressing K cyclin go through multiple rounds ofcultured for 3 days in the presence of serum. A significant frac-
tion of wt, E2F1/, and ARF/ MEFs expressing K cyclin DNA replication without cell division.
To confirm that the multinucleation and polyploidy inducedshowed increased ploidy, which was reflected by an increase
in the fraction of cells with approximately 8N DNA content (from by K cyclin are not phenomena peculiar to MEFs, we used
amphotropic retroviruses to introduce K cyclin into primary hu-3%–6% in mock-infected to around 22%–27% in K cyclin-
expressing cultures) (Figure 5A). p53/ MEFs showed in- man lung fibroblasts. As with MEFs, primary human fibroblasts
growth-arrested upon K cyclin expression (Figure 5B, uppercreased ploidy (14%) even in control, mock-infected cultures.
Importantly, expression of K cyclin also induced accumulation panel). This growth arrest was further confirmed by time-lapse
videomicroscopy (see the Supplementary Material). Further-of cells with an 8N DNA content in p53/ MEFs (up to the
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Figure 5. MEFs and MRC-5 cells expressing K
cyclin become polyploid
A: MEFs infected and grown as described in Fig-
ure 6A were grown for 3 days in 10% FBS-con-
taining medium. Adhered cells were harvested,
followed by staining of the DNA with PI and flow
cytometric analysis to establish cell cycle profiles.
The percentages of cells with a DNA content
greater than 4N are indicated. B: MRC-5 cells
transduced with empty or K cyclin-encoding ret-
rovirus were grown, and growth curves were de-
termined as described in Figure 4A. Cells cultured
for 3 days were harvested and analyzed by flow
cytometry as in A.
more, flow cytometric analysis of K cyclin-expressing human daughter cells. Centrosome amplifications can result in the for-
fibroblasts cultured for 3 days in the presence of serum showed mation of multiple spindles and consequent aberrant chromo-
the presence of a polyploid population of cells (Figure 5B, lower some separation and genomic instability and, in this way, poten-
panel). Taken together, we conclude that K cyclin expression tially promote tumorigenesis (Hinchcliffe and Sluder, 2001).
leads to the formation of a polyploid population of cells in both Interestingly, the centrosome duplication cycle has been linked
human and mouse primary fibroblasts. to cyclin E/A-driven cdk2 activity (Lacey et al., 1999; Matsumoto
et al., 1999; Meraldi et al., 1999). Since many K cyclin-express-
ing cells are multinucleated and K cyclin/Cdk activity resemblesCentrosome amplification in K cyclin-expressing MEFs
Cdk2 activity, we investigated whether K cyclin-expressing cellsIt has recently been shown that multinucleated cells often con-
exhibit an increased number of centrosomes.tain more than two centrosomes (Meraldi et al., 2002). Centro-
We analyzed the number of centrosomes in K cyclin-somes constitute the microtubule-organizing centers of the cell
and as such assure proper segregation of chromosomes to expressing cells by immunocytochemical staining of the
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Figure 6. Centrosome amplifications in K cyclin-
expressing MEFs
A: Wt or p53/ MEFs were infected with empty
or K cyclin-encoding vector, grown for 3 days on
coverslips, and stained with anti--tubulin anti-
body for centrosomes (green) and DAPI (blue)
for DNA. The numbersindicate the amounts of
centrosomes per cell. B: Quantitation of the cen-
trosome analysis described in A. The pooled per-
centages of three experiments of around 70 cells
each are shown.
centrosomal proteins -tubulin and centrin. Anti--tubulin stain- ing from 3 to 40 centrosomes per cell. Staining with an anti-
centrin antibody showed analogous results, confirming the spe-ing of MEFs expressing K cyclin show a marked increase in the
average number of centrosomes per cell above the expected cific staining of centrosomes (data not shown).
The DNA and centrosome replication cycles are thought tonumber of 1–2 centrosomes per normal cell (Figures 6A and
6B). While only 6.5% of mock-infected wt or 15.6% of p53/ be coregulated. To explore a potential correlation between the
number of centrosomes and the DNA content (N) per cell, weMEFs had more than two centrosomes, around 46% of wt MEFs
expressing K cyclin showed centrosome amplification. Amplifi- quantitated nuclear DNA content using quantitative immuno-
fluorescence microscopy. The normalized DNA content ofcation of centrosomes was typically observed in cells with large
or multiple nuclei (Figure 6A, middle panel). Loss of p53 exacer- mock-infected cultures shows values of N ranging from 2 to 4
(Figure 7A), validating the use of our method. In contrast, abated this phenotype, with around 67.5% of K cyclin-expressing
p53/ MEFs showing centrosome amplifications. The actual significant proportion of K cyclin-expressing cells have a DNA
content of around 8N, increasing in a few cells to around 16N,numbers of centrosomes observed were remarkably high, rang-
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Figure 7. Centrosome amplification correlates with ploidy and is associated with genomic abnormalities
A: Wt MEFs infected and grown as in Figure 7A were stained with anti--tubulin and PI. The DNA content per nucleus was measured by quantitative
immunofluorescence microscopy and was normalized to obtain an N  2 population. Around 100 mock-infected cells or 150 K cyclin-infected cells were
analyzed. The inset histogram illustrates that average numbers of centrosomes increase with DNA content. B: Example of the correlation analysis. The panel
shows a field of wt MEFs infected with K cyclin that were stained with -tubulin (green) and PI (red). The numbers before the slash represent DNA contents,
and the numbers after the slash represent centrosome counts. C: Confocal microsopic analysis of wt (first image) or p53/ MEFs (second and third image)
infected with K cyclin retrovirus and grown and stained as described in A. The pictures represent the image layer that best visualized the genomic
abnormality, magnification 63 and 2 zoom.
consistent with the flow cytometric analysis (Figure 5). We corre- human fibroblasts was also less pronounced (Figure 5B), consis-
tent with the finding that an increase in ploidy correlates withlated the DNA content of each individual cell with the number
of centrosomes in the same cell (inset in Figure 7A and Figure an increase in the number of centrosomes.
The presence of multiple centrosomes in one cell can lead7B). Notably, the cells with the highest DNA content contain
the highest number of centrosomes. Furthermore, cells with to the formation of multiple spindles and improper chromosome
separation. Indeed, confocal studies of our cells revealed theamplified centrosomes are always polyploid (inset in Figure 7A),
and these cells often contain a single, but very large, nucleus formation of multipolar spindles and, in p53/ cells, anaphase
bridges that were sometimes accompanied by chromosomal(Figure 7B).
Primary human fibroblasts also exhibited centrosome ampli- fragments (Figure 7C). We conclude that K cyclin expression
leads to genomic instability, involving increases in ploidy andfication upon K cyclin expression, although the numbers of
centrosomes per cell were not as high as with MEFs (maximum centrosome amplifications. Furthermore, such genomically un-
stable cells are viable and are able to expand in the absenceof six per cell, data not shown). However, the polyploidy in
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B or T cell lymphomas by around 7 months of age (E.W.V. et
al., unpublished data).
To determine whether loss of p53 exacerbates the onco-
genic action of K cyclin in vivo, E K cyclin transgenic mice
were bred with p53/ mice, and the progeny of different
genotypes were followed for the development of lymphoma.
During a 6-month follow-up period, none of the E K cyclin
transgenic mice with a p53/ genotype developed tumors.
The nontransgenic p53/ mice and the K cyclin-expressing
heterozygous p53/ mice developed lymphomas only at very
low frequency, with figures of 5/23 (21.7%) and 2/31 (6.5%),
respectively. In striking contrast, all E K cyclin transgenic mice
with a p53/ genotype rapidly developed T cell (20 mice) or
B cell lymphomas (1 mouse) with a mean latency of around
85–90 days (Figure 8B). Thus, the oncogenic potential of K
cyclin is revealed in vivo by loss of p53.
Discussion
The unique features of K cyclin/Cdk complexes, including their
resistance to Cdk inhibitors and promiscuous phosphorylation
of target proteins, are believed to contribute to pathogenesis
Figure 8. E K cyclin cooperates with p53 loss in tumorigenesis
of KSHV by enhancing the proliferative potential of the host B
A: A graphic representation of the transgenic cassette used to generate
lymphocytes and endothelial cells latently infected with the virusE K cyclin transgenic founders. B: Kaplan Meier survival curves of K cyclin
(Ellis et al., 1999; Mann et al., 1999; Swanton et al., 1997).transgenic p53/, p53/, or p53/ mice and nontransgenic controls.
All K cyclin/p53/ mice developed lymphoblastic lymphomas. Despite this, there has been no direct demonstration of an onco-
genic function for K cyclin. Our results suggest that the innate
oncogenic activity of K cyclin may be suppressed by its induc-
tion of p53-dependent apoptosis and growth arrest. Consistent
of p53, explaining the exacerbation of the K cyclin-associated with this, we show for the first time that K cyclin can act as an
phenotype in p53/ MEFs. oncogene in vivo, but only in the absence of the p53 tumor
suppressor.
Loss of p53 cooperates with K cyclin We confirm the previous results of Ojala and colleagues
in murine lymphomagenesis (Ojala et al., 1999) that demonstrated that constitutive expres-
Our in vitro results show that loss of p53 promotes the survival sion of K cyclin engages the apoptotic machinery, consistent
and outgrowth of K cyclin-expressing cells with unstable ge- with the paradigm of activation of dual opposing pathways by
nomes. This suggests that K cyclin could be especially tumori- oncoproteins. However, while cotransfection of K cyclin with
genic in a p53 null background in vivo. To test this hypothesis, Cdk6 in human cell lines triggered apoptosis directly (Ojala et
we created a transgenic mouse strain expressing K cyclin under al., 1999), in our studies, K cyclin expression in mouse embryo
the E promoter (Figure 8A). These transgenic mice express K fibroblasts elicited little apoptosis alone but acted to sensitize
cyclin protein not only in splenic B cells, but also in splenic and cells to various triggers of apoptosis (Figure 1). Therefore, induc-
tion of apoptosis upon K cyclin expression depends on cellthymic T cells. Around 10% of K cyclin transgenic mice develop
Figure 9. Model showing how expression of K
cyclin in MEFs triggers multiple responses
We speculate that cells expressing K cyclin un-
dergo abortive cytokinesis (the mechanism of
which is unknown) and adapt from the cytokine-
sis defect and become tetraploid. This may trig-
ger the activation of p53 and concurrent
(p21Cip1-independent) growth arrest and sensiti-
zation to apoptosis. Because K cyclin is insensitive
to the action of Cdk inhibitors such as p21Cip1,
growth-arrested cells lack functional G1 and G2
checkpoints. This leads to the formation of a
polyploid/aneuploid population of cells with am-
plified centrosomes, which survives and expands
in the absence of p53 to become tumorigenic.
Additional apoptotic triggers like the phosphory-
lation and inactivation of endogenous Bcl-2 are
likely to contribute to the final fate of K cyclin-
expressing cells.
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type, and presumably the spectrum of endogenous Cdks and although it must involve p53-regulated genes other than p21Cip1
since p21/ MEFs arrest upon K cyclin expression.the presence of apoptotic stimuli in the cellular environment.
K cyclin-expressing p53/ and wt MEFs show massiveExpression of K cyclin resulted in the upregulation of tran-
centrosome amplification to an extent that has hitherto not beenscriptionally active p53 protein and concomitant growth arrest
observed. In addition, many K cyclin-expressing cells exhibitedand apoptosis. K cyclin/Cdk complexes stimulate the hyper-
multiple spindles and anaphase bridges, indicative of genomicphosphorylation of Rb and thus catalyze the release of E2Fs,
instability. Recently, defects in cell division and concomitantincluding E2F1, a transcriptional activator of the human p14ARF
multinucleation were shown to give rise to centrosome amplifi-promoter (Bates et al., 1998). We therefore hypothesized that
cations (Meraldi et al., 2002). We also find that many polyploidK cyclin induces p53 stabilization via E2F1-dependent upregula-
K cyclin-expressing cells contain amplified numbers of centro-tion of p19ARF protein. However, neither the accumulation of p53
somes. In our case, cells with the highest DNA content oftenprotein nor apoptosis or growth arrest upon K cyclin expression
contained one large nucleus (Figure 7B), adding to the modelrequires the presence of either E2F1 or p19ARF, implying that K
of Meraldi and colleagues in which ploidy, rather than multinu-cyclin activates p53 through a different mechanism.
cleation, correlates with centrosome number. It therefore seemsTime-lapse videomicroscopic analysis of K cyclin-express-
likely that K cyclin expression promotes chromosome instabilitying cells shows that, although such cells do not divide, many
via the formation of polyploid cells, although K cyclin may alsocells still undergo nuclear divisions or contain an enlarged nu-
directly drive centrosome amplifications independent of DNAcleus. In addition, many K cyclin-expressing cells show ongoing
synthesis.DNA replication together with ploidy increase, implying that cells
We suggest that K cyclin expression promotes DNA replica-reenter S phase without undergoing cytokinesis. This may relate
tion and polyploidy in cells, which then triggers p53-dependentto the so-called “adaptation” of cells after spindle disruption,
apoptosis and growth arrest (see the model in Figure 9). Thus,in which cells reenter G1 even though cytokinesis is disrupted
in the absence of p53, a polyploid population of cells is able to(Lanni and Jacks, 1998). Interestingly, in such cases, tetraploidy
survive and expand. We therefore hypothesized that K cyclintriggers the activation of p53, presumably acting as a safeguard
would promote tumorigenesis only when p53 is absent. This ismechanism to eliminate the survival of a polyploid/aneuploid
supported by our transgenic mouse model in which K cyclinpopulation of cells (Andreassen et al., 2001). Thus, K cyclin-
expression is regulated by the E promoter. In wild-type mice,associated tetraploidy may similarly trigger the activation of p53.
a low level of lympoma induction with a long latent period isWhen cytokinesis is aborted by spindle disruption, p53 arrests
seen. In contrast, loss of p53 results in a substantial decreasethe two daughter nuclei in G1 via the induction of the p21Cip
in latency and increases the incidence of K cyclin-induced lym-protein and inhibition of cyclin/Cdk activity (Andreassen et al.,
phomas. Loss of p53 leads to inhibition of apoptosis, inhibition2001). However, K cyclin/Cdk complexes are refractory to Cdk
of growth arrest, and promotion of aneuploidy, all of which couldinhibitors, including p21Cip1 (Swanton et al., 1997), and, as a
contribute to K cyclin-induced tumorigenesis. It has recentlyconsequence, the p53-induced checkpoint is ignored, such that
been suggested that it is the inhibition of apoptosis, ratherK cyclin-expressing cells undergo multiple rounds of DNA repli-
than the acquisition of aneuploidy, that constitutes the criticalcation and become polyploid. This situation would be analogous
tumorigenic effect of p53 loss (Gurova et al., 2002; Schmitt etto the endoreduplication upon spindle disruption in p53/ or
al., 2002). Whether the same is also true for the exacerbationp21/ cells (Di Leonardo et al., 1997; Khan and Wahl, 1998;
of K cyclin-induced oncogenicity that we see upon p53 ablationLanni and Jacks, 1998; Stewart et al., 1999) or upon a Ras-
remains to be seen.induced growth arrest in p21//p27/ MEFs (Groth et al.,
In the context of KSHV physiology, it is interesting to note2000). Taken together, our results favor a model in which p53
that two of the five latently expressed HHV-8 proteins (LANAis activated upon K cyclin-induced tetraploidy, and not through
and ORF K10) bind p53 and can inhibit its ability to inducethe E2F1/ARF pathway.
transcriptional activation (Friborg et al., 1999; Rivas et al., 2001).It remains unclear what triggers the cytokinesis defect upon
Furthermore, LANA has been shown to colocalize with p53 inK cyclin expression. Unlike in yeast, where the mechanism of
KS cells (Katano et al., 2001). Thus, our finding that the mito-cytokinesis mediated by the “mitotic exit network (MEN)” pro-
genic effects of K cyclin are blocked by p53 may offer an expla-teins has been extensively studied, the mode of regulation of
nation for the presence of this set of p53-inhibiting proteins incytokinesis in mammalian cells is largely unknown. It is clear,
the KSHV genome. Taken together, our data provide the firsthowever, that proper orchestration of mitotic cyclin/Cdk activity
evidence for an in vivo oncogenic function of the KSHV cyclinis essential for cells to undergo cytokinesis. In particular, the
and suggest that the inhibition of the p53 tumor suppressormitotic cyclins A and B need to be targeted for degradation
pathway is an important attribute of K cyclin-induced tumori-via ubiquitination by the anaphase-promoting complex (APC)
genesis.(Morgan, 1999). We presume that premature or constitutive K
cyclin-driven Cdk2-like activity deregulates the timing of the Experimental procedures
mitotic machinery, thus resulting in defective cytokinesis. Sup-
porting this, recent evidence points at a correlation between the Cell culture and treatment
E2F1/ (Field et al., 1996), p53/ (Jacks et al., 1994), and p21/formation of multinucleated cells and deregulated expression of
mice (Brugarolas et al., 1995) were obtained from The Jackson Laboratory.mitotic regulators that impinge either directly on spindle forma-
P19ARF/ mice were obtained from F. McCormick and were originally fromtion or on mitotic cyclin stability (Meraldi et al., 2002; Zhang
C. Sherr (Kamijo et al., 1997). MEFs from nullizygous and wild-type (C57BL/6
and Lees, 2001). In addition, the finding that K cyclin-expressing or C57BL/6  129) controls were derived from 12- to 14-day-old embryos
p53/ MEFs continue to divide implies a role for p53 in the and were genotyped using PCR protocols supplied by the labs that gener-
ated the mice. MEFs were maintained on a 3T9 protocol (Todaro and Green,regulation of cytokinesis. The possible mechanism is unclear,
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1963). Phoenix-Eco and -Ampho retrovirus packaging cells (gift from G. activity 1.2  107 U/mg, kindly provided by Boehringer-Ingelheim), His-
tagged TRAIL (200 ng/ml, R&D Systems), or etoposide (5 M, Sigma) toNolan), MEFs, and MRC-5 primary human lung fibroblasts were maintained
in Dulbecco’s modified Eagle’s medium (DMEM, GIBOCO-BRL), supple- trigger apoptosis. TRAIL ligand was preincubated for 30 hr at room tempera-
ture with 3 g anti-6x Histidine antibody (R&D systems) to initiate ligandmented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 g/ml
streptomycin, and 100 U/ml penicillin. Cells were cultured at 37	C in 5% trimerization. Cells and supernatants were collected and stained with
Annexin V-PE (Pharmingen) according to the manufacturer’s protocol. DNACO2. When indicated, cells were exposed to 8 Gy of -irradiation using a
Cs irradiator (Mark 1, Model 68 SN.1019, J.L. Shepherd & Associates). was counterstained with Via-Probe (20 l per sample, Pharmingen). The
percentage of Annexin V-positive/Via-Probe positive or negative cells in
the GFP-expressing population of cells was determined by flow cytometricPlasmids
analysis.The retroviral vector pBabepuro and double Flag-tagged human cyclin D3
and K cyclin in pBabepuro were gifts from D. Mann. Double Flag-tagged K
cyclin was subcloned from KpcDNA3 (Mann et al., 1999) and was ligated Time-lapse videomicroscopic analysis of cells
MEFs or MRC-5 cells were plated at 1  105 cells per well in a 6-well plate.in the bicistronic retroviral pBMNIresEGFP vector (gift from F. Rossi), creating
Cells were grown in a humidified system adapted with a CTI-controller (5%KpBMN.
CO2) and a 37-2 digital Tempcontrol (37	C) on an Axiovert S 100 microscope
(all systems from Zeiss). About 20–40 cells were followed over the courseGeneration of E K cyclin transgenic mice
of 4 days while taking photos (magnification 10) every 10 min using anDouble Flag-tagged K cyclin cDNA was amplified by PCR from KpcDNA3
Openlab automator module (Improvision). Time-lapse videos were compiledplasmid using primers containing 5
 XhoI and 3
BamHI sites. Restricted PCR
in Openlab and were converted to QuickTime movies (0.1 s per frame).product was ligated into SalI and BamHI cut pHSE3
 plasmid (a generous
gift from R. Zinkernagel), creating K cyclin pHSE3, which drives transgene
Immunoblotting of cell lysatesexpression from the H-2K promoter/Ig-enhancer cassette (also called E).
Cells were washed with PBS and were lysed in boiling lysis buffer (2.5%Expression of K cyclin was confirmed in mouse A20 B cells transiently
SDS in 0.5 M Tris-HCl [pH 6.8]). Lysates were sonicated and cleared bytransfected with K cyclin pHSE3
 plasmid. XhoI-linearized K cyclin PHSE3

centrifugation. Protein concentrations were determined using a BioRad DCwas agarose gel purified using Jetsorb (Genomed), followed by purification
assay according to the manufacturer’s protocol. Proteins (20 g) were frac-using the Wizard DNA clean-up system (Promega). DNA was resuspended
tionated by SDS-PAGE and were transferred to PVDF membranes (Millipore).at a concentration of 5 ng/l in sterile injection buffer (10 mM Tris, 0.1
Membranes were probed with polyclonal antibodies directed to mouse p53mM EDTA [pH 7.4]), microinjected into the male pronucleus of around 200
(CM5, Novocastra), p19ARF (AbCam), or p21Cip1 (Pharmingen) or monoclonalfertilized oocytes, and implanted in foster mothers. Potential (CBA 
antibodies directed to Flag (M2, Sigma) or -actin (Sigma). Antibody bindingC57BL/6) F1 founder animals were screened for the presence of the K cyclin
was visualized by enhanced chemiluminescence (ECL).cDNA by Southern blot analysis, and positive animals were outbred to F1
animals to establish founder lines. Two founder lines (called E K cyclin
Centrosome immunohistochemistry and DNA quantitation1996E-H [6] and E K cyclin 2269A.1 [20]) expressing high levels in either
MEFs grown on coverslips were fixed in ice-cold methanol for 6 min atthe splenic B cells or in the thymic T cells were identified. The results shown
20	C. Coverslips were washed with PBS, and cells were permeabilized inhere are from founder 1996E-H (6).
0.1% Tween-20/PBS, followed by staining for 1 hr at room temperature with
anti -tubulin (1:150, Sigma) or anti-centrin (1:500, generous gift from J.L.Retroviral infection, growth curves, flow cytometric analysis,
Salisbury) primary antibody diluted in 0.5% NP-40/10% goat serum/PBS.and apoptosis
After washing and another permeabilization step, primary antibody bindingRetroviral supernatants were produced by transfection of Phoenix-Eco or
was detected using a donkey anti-mouse Alexa Fluor 488 goat anti-mousePhoenix-Ampho retrovirus-producing cells with 4 g retroviral vector using
secondary antibody (1:200, Molecular Probes). DNA was counterstainedLipofectamine Plus reagent (GIBCO-BRL). Supernatants were harvested
with DAPI (4’,6-diamidino-2-phenylindole, 0.5 M, Sigma), and coverslips40–48 hr after transfection and filtered, and polybrene (Sigma) was added
were mounted in MOWIOL (Calbiochem), followed by microscopic analysis.to a final concentration of 10 g/ml. Passage 2–4 MEFs were plated at 1 
Around 70 cells from three experiments were analyzed, and the data were105 cells per well in a 6-well plate or 1  106 cells per 10-cm dish and were
pooled to calculate averages. When indicated, slides were analyzed byinfected the next day with 1 ml/well or 5.5 ml/dish of freshly harvested virus.
confocal microscopy using a Zeiss LSM 510 META microscope.MRC-5 cells were plated at 1  106 cells per 10-cm dish and were infected
For quantitation of cellular DNA contents, DNA was counterstained withthe next day with 5.5 ml freshly harvested virus. For growth curve analysis
PI (3 g/ml, 100 U/ml Ribonuclease A) for 30 min at room temperature.or for Western blot analysis (see below), MEF cells were infected for 18–24
Immunofluoresence microscopy was performed, and the DNA content ofhr. MRC-5 cells were infected for 9 hr. Infected MEFs were selected by
individual nuclei was measured using the particle analysis tool of Sciongrowth for 48 hr in medium containing 5 g/ml puromycin. Infected MRC-5
Image 1.62c software by integrating the PI signal density of separate particle.cells were trypsinized and seeded at 1:3 dilution in medium containing 5
Overlapping nuclei or nuclei touching the edges were ignored. Identicalg/ml puromycin. The absence of reverse transcriptase activity in culture
threshold limits were used for all analyses to standardize background signals.supernatants of infected MRC-5 cells was confirmed 72 hr after antibiotic
selection using the Quan-T-RT assay according to the manufacterer’s proto-
DNA replication analysiscol (Amersham). MEFs or MRC-5 cells were plated at a density of 0.5  105
For measurements of DNA replication, cells were infected and grown for 3cells per well in 6-well plates and were counted at 1, 3, and 5 days after
days essentially as described for growth curve analysis. A total of 50 Mplating to establish growth curves. Alternatively, DNA was stained with
of 5-bromodeoxyuridine (BrdU, Sigma) was added to the medium, and cellsHoechst 33342 dye (Sigma), followed by microscopic analysis.
were grown for an additional 5 hr. For flow cytometric analysis, cells wereTo assess the effect of K cyclin expression on DNA content, cells in-
trypsinized, washed twice in 1% BSA/PBS, fixed with cold 70% ethanol,fected as above were plated at a density of 0.8  106 cells per 10-cm dish
and stored at 20	C. For microscopic analysis, cells grown on coverslips(MEFs) or 0.5  105 cells per well (MRC-5) and were grown for 3 days until
were fixed with 70% ethanol for 30 min at room temperature. BrdU incorpora-harvesting. Cells were washed twice with PBS and were fixed in 70% ethanol.
tion was determined with an anti-BrdU-FITC conjugate (Becton Dickinson)Cells were resuspended in PBS containing 10 g/ml propidium iodide (PI),
according to the manufacturer’s protocol. BrdU incorporation was measured100 U/ml Ribonuclease A (Sigma), and 0.1% glucose (Sigma) and were
by flow cytometric analysis or fluorescence microscopy.immediately analyzed by flow cytometry.
For apoptosis assays, MEFs were infected for 8 hr with fresh pBMNIres-
EGFP virus supernatant, followed by overnight incubation in normal growth Acknowledgments
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